Primary hyperaldosteronism Screening: Difference between revisions

Jump to navigation Jump to search
 
(6 intermediate revisions by 3 users not shown)
Line 4: Line 4:


==Overview==
==Overview==
There is insufficient evidence to recommend routine screening for primary hyperaldosteronism but according to the Endocrine Society Clinical Practice Guideline, screening for hyperaldosteronism is recommended for resistant hypertension by checking the plasma aldosterone to renin ratio (PAC/PRA).


==Screening==
==Screening==


=== Screening population ===
=== Screening population ===
The following indviduals should be screened for primary hyperaldosteronism:<ref name="pmid3230101">{{cite journal |vauthors=Horsley MG, Bailie GR |title=Effectiveness of theophylline monitoring by the use of serum assays |journal=J Clin Pharm Ther |volume=13 |issue=5 |pages=359–64 |year=1988 |pmid=3230101 |doi= |url= |issn=}}</ref>
The following individuals should be [[Screening (medicine)|screened]] for primary hyperaldosteronism:<ref name="pmid3230101">{{cite journal |vauthors=Horsley MG, Bailie GR |title=Effectiveness of theophylline monitoring by the use of serum assays |journal=J Clin Pharm Ther |volume=13 |issue=5 |pages=359–64 |year=1988 |pmid=3230101 |doi= |url= |issn=}}</ref>
# Blood pressure > 160 / 100 particularly (< 50 years)
* [[Blood pressure]] > 160/100 (particularly in age < 50 years)
# Resistant hypertension or refractory hypertension (use of > 3 anti-hypertensives and poor control of blood pressure)
* Resistant [[hypertension]] or refractory [[hypertension]] (use of > 3 [[Antihypertensive|anti-hypertensives]] and poor control of [[blood pressure]])
# Hypokalemia (provoked by diuretic therapy or unprovoked)
* [[Hypokalemia]] (provoked by [[diuretic]] therapy or unprovoked)
# Hypertension and incidentally discovered adrenal adenoma
* [[Hypertension]] and incidentally discovered [[Adrenal gland|adrenal]] [[adenoma]]
# Hypertension with a family history of early-onset hypertension (< 20 years) or cerebrovascular accident at age less than 40 years
* [[Hypertension]] with a family history of early-onset [[hypertension]] (< 20 years) or [[Cerebrovascular disease|cerebrovascular]] accident at age less than 40 years
# Hypertensive first-degree relatives of patients with PA
* [[Hypertension|Hypertensive]] first-degree relatives of patients with primary aldosteronism (PA)


=== Plasma Aldosterone to Renin Ratio (PAC/PRA) ===
=== Plasma Aldosterone to Renin Ratio (PAC/PRA) ===
The [[Blood plasma|plasma]] [[aldosterone]] to [[renin]] ratio is widely used as a [[Screening (medicine)|screening]] test for hyperaldosteronism.<ref name="pmid22167725">{{cite journal |vauthors=Ríos MC, Izquierdo A, Sotelo M, Honnorat E, Rodríguez Cuimbra S, Catay E, Popescu BM |title=[Aldosterone/renin ratio in the diagnosis of primary aldosteronism] |language=Spanish; Castilian |journal=Medicina (B Aires) |volume=71 |issue=6 |pages=525–30 |year=2011 |pmid=22167725 |doi= |url= |issn=}}</ref><ref name="pmid24526370">{{cite journal |vauthors=Pilz S, Kienreich K, Gaksch M, Grübler M, Verheyen N, Bersuch LA, Schmid J, Drechsler C, Ritz E, Moosbrugger A, Stepan V, Pieber TR, Meinitzer A, März W, Tomaschitz A |title=Aldosterone to active Renin ratio as screening test for primary aldosteronism: reproducibility and influence of orthostasis and salt loading |journal=Horm. Metab. Res. |volume=46 |issue=6 |pages=427–32 |year=2014 |pmid=24526370 |doi=10.1055/s-0034-1367033 |url= |issn=}}</ref><ref name="urlThe Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline: The Journal of Clinical Endocrinology & Metabolism: Vol 101, No 52">{{cite web |url=http://press.endocrine.org/doi/10.1210/jc.2015-4061 |title=The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline: The Journal of Clinical Endocrinology & Metabolism: Vol 101, No 5 |format= |work= |accessdate=}}</ref>


==== Protocol ====
==== Protocol ====
* Drugs that affect the renin–angiotensin-aldosterone axis should be stopped before testing, such as: beta-blockers, ACE inhibitors, ARBs (angiotensin receptor blockers), renin inhibitors, dihydropyridine calcium channel blockers, and central alpha2-agonists, for about fourteen days, and spironolactone, eplerenone, amiloride, and triamterene, and loop diuretics for about twenty eight days.
* Drugs that affect the [[Renin angiotensin aldosterone system|renin–angiotensin-aldosterone axis]] should be discontinued before testing, such as [[Beta blockers|beta-blockers]], [[ACE inhibitor|ACE inhibitors]], [[ARBs]] ([[angiotensin receptor blockers]]), [[Renin inhibitor|renin inhibitors]], [[Calcium channel blockers|dihydropyridine calcium channel blockers]], and central [[Alpha2-adrenergic agonists|alpha 2-agonists]], for about fourteen days, and [[spironolactone]], [[eplerenone]], [[amiloride]], and [[triamterene]], and [[Loop diuretic|loop diuretics]] for about twenty eight days.
* The test should be conducted between 8 a.m. and 10 a. m. The patient is advised to stay upright for 2 hours prior to testing, and then sit for about 10 minutes before testing.<sup>[[Primary hyperaldosteronism laboratory findings#cite note-pmid11881117-1|[1]]]</sup>
* The test should be conducted between 8 AM and 10 AM. The patient is advised to stay upright for 2 hours prior to testing, and then sit for about 10 minutes before testing.<sup>[[Primary hyperaldosteronism laboratory findings#cite note-pmid11881117-1|[1]]]</sup>


==== Interpretation ====
==== Interpretation ====
* Primary hyperaldosteronism (Conn's syndrome) is associated with an increased aldosterone levels (PAC) in plasma along with suppressed renin concentration (PRA) due to feedback inhibition of aldosterone on renin levels in the plasma.
* Primary hyperaldosteronism (Conn's syndrome) is associated with an increased [[aldosterone]] levels (PAC) in [[Blood plasma|plasma]] along with suppressed [[renin]] concentration (PRA) due to [[feedback inhibition]] of [[aldosterone]] on [[renin]] levels in the [[Blood plasma|plasma]].
* A PAC/PRA ratio of >30 is a strong evidence of primary hyperladosteronism and value >50 is considered diagnostic in the presence of resistant hypertension, hypokalemia and metabolic alkalosis.
* A PAC/PRA ratio of > 30 is a strong evidence of primary hyperaldosteronism and value > 50 is considered diagnostic in the presence of resistant [[hypertension]], [[hypokalemia]], and [[metabolic alkalosis]].<ref name="pmid16617310">{{cite journal |vauthors=Doi SA, Abalkhail S, Al-Qudhaiby MM, Al-Humood K, Hafez MF, Al-Shoumer KA |title=Optimal use and interpretation of the aldosterone renin ratio to detect aldosterone excess in hypertension |journal=J Hum Hypertens |volume=20 |issue=7 |pages=482–9 |year=2006 |pmid=16617310 |doi=10.1038/sj.jhh.1002024 |url= |issn=}}</ref><ref name="pmid245263702">{{cite journal |vauthors=Pilz S, Kienreich K, Gaksch M, Grübler M, Verheyen N, Bersuch LA, Schmid J, Drechsler C, Ritz E, Moosbrugger A, Stepan V, Pieber TR, Meinitzer A, März W, Tomaschitz A |title=Aldosterone to active Renin ratio as screening test for primary aldosteronism: reproducibility and influence of orthostasis and salt loading |journal=Horm. Metab. Res. |volume=46 |issue=6 |pages=427–32 |year=2014 |pmid=24526370 |doi=10.1055/s-0034-1367033 |url= |issn=}}</ref>


==References==
==References==

Latest revision as of 16:59, 3 November 2017

Primary hyperaldosteronism Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Primary Hyperaldosteronism from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic study of choice

History and Symptoms

Physical Examination

Laboratory Findings

CT scan Findings

MRI Findings

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Case Studies

Case #1

Primary hyperaldosteronism Screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Primary hyperaldosteronism Screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Primary hyperaldosteronism Screening

CDC on Primary hyperaldosteronism Screening

Primary hyperaldosteronism Screening in the news

Blogs on Primary hyperaldosteronism Screening

Directions to Hospitals Treating Conn syndrome

Risk calculators and risk factors for Primary hyperaldosteronism Screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Syed Hassan A. Kazmi BSc, MD [2]

Overview

There is insufficient evidence to recommend routine screening for primary hyperaldosteronism but according to the Endocrine Society Clinical Practice Guideline, screening for hyperaldosteronism is recommended for resistant hypertension by checking the plasma aldosterone to renin ratio (PAC/PRA).

Screening

Screening population

The following individuals should be screened for primary hyperaldosteronism:[1]

Plasma Aldosterone to Renin Ratio (PAC/PRA)

The plasma aldosterone to renin ratio is widely used as a screening test for hyperaldosteronism.[2][3][4]

Protocol

Interpretation

References

  1. Horsley MG, Bailie GR (1988). "Effectiveness of theophylline monitoring by the use of serum assays". J Clin Pharm Ther. 13 (5): 359–64. PMID 3230101.
  2. Ríos MC, Izquierdo A, Sotelo M, Honnorat E, Rodríguez Cuimbra S, Catay E, Popescu BM (2011). "[Aldosterone/renin ratio in the diagnosis of primary aldosteronism]". Medicina (B Aires) (in Spanish; Castilian). 71 (6): 525–30. PMID 22167725.
  3. Pilz S, Kienreich K, Gaksch M, Grübler M, Verheyen N, Bersuch LA, Schmid J, Drechsler C, Ritz E, Moosbrugger A, Stepan V, Pieber TR, Meinitzer A, März W, Tomaschitz A (2014). "Aldosterone to active Renin ratio as screening test for primary aldosteronism: reproducibility and influence of orthostasis and salt loading". Horm. Metab. Res. 46 (6): 427–32. doi:10.1055/s-0034-1367033. PMID 24526370.
  4. "The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline: The Journal of Clinical Endocrinology & Metabolism: Vol 101, No 5".
  5. Doi SA, Abalkhail S, Al-Qudhaiby MM, Al-Humood K, Hafez MF, Al-Shoumer KA (2006). "Optimal use and interpretation of the aldosterone renin ratio to detect aldosterone excess in hypertension". J Hum Hypertens. 20 (7): 482–9. doi:10.1038/sj.jhh.1002024. PMID 16617310.
  6. Pilz S, Kienreich K, Gaksch M, Grübler M, Verheyen N, Bersuch LA, Schmid J, Drechsler C, Ritz E, Moosbrugger A, Stepan V, Pieber TR, Meinitzer A, März W, Tomaschitz A (2014). "Aldosterone to active Renin ratio as screening test for primary aldosteronism: reproducibility and influence of orthostasis and salt loading". Horm. Metab. Res. 46 (6): 427–32. doi:10.1055/s-0034-1367033. PMID 24526370.

Template:WH Template:WS